Clearbridge BioMedics is a clinical oncology company that enables non-invasive liquid biopsy using a label-free Circulating Tumour Cell (CTC) enrichment platform. It is a National University of Singapore (NUS) spin-off company committed to revolutionizing cancer diagnostics and patient care. The ClearCell® FX System, using the CTChip®, is based on innovative technology that effectively isolates intact and viable CTCs from patients’ blood. The system uses inertial focusing microfluidics for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells to be used for cancer diagnosis and treatment monitoring. By enriching CTCs from standard blood samples, the platform allows for analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of precision medicine.
Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. The company has won numerous awards and garnered global recognition for the ClearCell® FX System. Clearbridge BioMedics has received ISO 13485 certification in 2011, and the ClearCell® FX attained CE IVD in 2015.